HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuki Muraoka Selected Research

N-acetyltryptophanamide (NATA)

4/2022Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy.
11/2020Factors associated with extremely poor visual outcomes in patients with central retinal vein occlusion.
1/2018Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema following Central Retinal Vein Occlusion: 1 Initial Injection versus 3 Monthly Injections.
4/2017RANIBIZUMAB FOR MACULAR EDEMA AFTER BRANCH RETINAL VEIN OCCLUSION: One Initial Injection Versus Three Monthly Injections.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuki Muraoka Research Topics

Disease

20Macular Edema
01/2022 - 01/2011
20Retinal Vein Occlusion
01/2022 - 01/2011
6Retinitis Pigmentosa (Pigmentary Retinopathy)
02/2018 - 01/2012
5Retinal Detachment (Retinal Detachments)
01/2016 - 06/2011
4Retinal Degeneration
02/2018 - 01/2012
4Glaucoma
02/2018 - 11/2011
3Macular Degeneration (Age-Related Maculopathy)
01/2022 - 05/2018
3Epiretinal Membrane (Epiretinal Membranes)
04/2019 - 04/2015
3Ganglion Cysts (Ganglion)
12/2018 - 11/2011
3Eye Diseases (Eye Disease)
02/2018 - 08/2014
3Vision Disorders (Hemeralopia)
01/2018 - 01/2016
2Polypoidal Choroidal Vasculopathy
06/2022 - 04/2022
2Retinal Arterial Macroaneurysm
03/2022 - 09/2021
2Myopia
01/2022 - 04/2015
2Diabetic Retinopathy (Retinopathy, Diabetic)
01/2020 - 04/2014
2Disease Progression
05/2018 - 04/2016
2Blindness (Hysterical Blindness)
02/2018 - 01/2016
2Neurodegenerative Diseases (Neurodegenerative Disease)
02/2018 - 08/2014
2Hemorrhage
03/2017 - 01/2015
1Infections
07/2022
1COVID-19
07/2022
1Atrophy
04/2022
1Inflammation (Inflammations)
03/2022
1Retinal Artery Occlusion
01/2020
1Choroidal Neovascularization
11/2018
1Paralysis (Palsy)
02/2018
1Refractive Errors (Refractive Error)
09/2017
1Retinal Diseases
01/2017
1Ischemic Optic Neuropathy (Anterior Ischemic Optic Neuropathy)
01/2017
1Retinal Hemorrhage
01/2016
1Obesity
12/2015
1Hypertension (High Blood Pressure)
12/2015
1Cysts
04/2015

Drug/Important Bio-Agent (IBA)

30Retinaldehyde (Retinal)IBA
03/2022 - 06/2011
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2022 - 01/2016
7Ranibizumab (Lucentis)FDA Link
06/2021 - 01/2015
4N-acetyltryptophanamide (NATA)IBA
04/2022 - 04/2017
4KUS121IBA
01/2020 - 01/2016
3Adenosine Triphosphate (ATP)IBA
05/2018 - 08/2014
2afliberceptIBA
12/2021 - 01/2018
2Fluorescein (Funduscein)FDA LinkGeneric
06/2021 - 05/2012
2Neuroprotective AgentsIBA
01/2020 - 04/2016
2Branched-Chain Amino AcidsIBA
02/2018 - 01/2018
2Rhodopsin (Visual Purple)IBA
01/2016 - 01/2012
2Bevacizumab (Avastin)FDA Link
10/2012 - 01/2011
1Prednisolone (Predate)FDA LinkGeneric
07/2022
11-phenyl-3,3-dimethyltriazene (PDT)IBA
04/2022
1Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
11/2020
1insulin receptor-related receptor (IRR)IBA
02/2018
1Biomarkers (Surrogate Marker)IBA
10/2017
1Pharmaceutical PreparationsIBA
01/2017
1Adenosine Triphosphatases (ATPase)IBA
04/2016
1SaltsIBA
12/2015
1Phosphates (Orthophosphate)IBA
12/2015
1CreatinineIBA
12/2015
1Antihypertensive Agents (Antihypertensives)IBA
12/2015
1N-Methylaspartate (NMDA)IBA
11/2011

Therapy/Procedure

8Therapeutics
01/2022 - 01/2016
7Aftercare (After-Treatment)
03/2022 - 01/2011
7Injections
06/2021 - 04/2017
3Intravitreal Injections
12/2021 - 01/2017
2Lasers (Laser)
10/2017 - 06/2014
2Vitrectomy
04/2014 - 09/2012
1Photochemotherapy (Photodynamic Therapy)
04/2022
1Slit Lamp
03/2022
1Traction
04/2015
1Light Coagulation
01/2011